Built on Atlas AI, the intelligence layer of the Octagos platform, Ask Atlas gives care teams a faster and more intuitive way to understand what is happening across their patient population, workflows, and clinic operations. Instead of relying on static reports, data tables, manual chart review, or custom analytics requests, clinicians and administrators can ask direct questions and receive clear, structured answers within seconds.

Ask Atlas is designed for the realities of modern device clinics, where care teams are managing growing transmission volumes, complex patient populations, disconnected workflows, and increasing pressure to do more with limited clinical resources.

Ask Atlas was previewed at the Heart Rhythm Society meeting in April 2026, where Octagos presented a new way for device clinics to interact with their own data.

“Remote monitoring has given clinicians more data than ever before, but access to data is not the same as understanding it,” said Dr. Shanti Bansal, founder and CEO of Octagos. “Ask Atlas gives care teams a way to ask the questions that matter in real time. That kind of direct access to their own data changes how a care team can understand, manage, and act on its own information.”

Also Read: Canvas Medical Launches Studio to Enable Clinicians and Operators to Customize and Extend EMR Workflows in Canvas

Octagos pioneered human-in-the-loop AI in cardiac remote monitoring through its Two-Brain Approach, a model powered by Atlas AI and strengthened by IBHRE-certified human expertise. Atlas AI assists in the rapid interpretation of cardiac device transmissions by surfacing clinically relevant findings and structuring reports for efficient review. IBHRE-certified specialists provide clinical oversight and expertise. In peer-reviewed data published in JACC: Advances, Octagos’ Two-Brain Approach demonstrated greater than 99% specificity, sensitivity, and accuracy, significantly outperforming human experts alone.

Ask Atlas brings natural language data access to device clinic operations, allowing clinicians to query recorded clinical and operational data held in the Octagos platform. The tool allows clinicians, administrators, and operational leaders to ask complex questions across their full remote monitoring dataset, including device transmissions, EHR data, clinical context, follow-up activity, workflow status, and billing information using natural language.

Example questions Ask Atlas can answer:

• “Which ICD patients have an EF <30% and are not on GDMT?”
• “Which patients received ICD shocks in the past 30 days without a scheduled follow-up?”
• “Which patients’ AF burden was over 2% and are not on anticoagulants?”
• “What is the average battery longevity of our devices by manufacturer and model?”
• “Which remote monitoring events qualified for billing but have not been e-signed?”

“AI has changed what people expect from technology: it should help people understand what matters and act on it,” said Haley Chute, Chief Product and Marketing Officer at Octagos. “That same shift is happening in cardiac remote monitoring. Since 2020, Atlas AI has helped device clinics streamline workflows, accelerate clinical reporting, and improve patient care. Ask Atlas advances that vision by helping care teams surface insights in their own data at the moment of need, bringing them closer to the answers and context they need to care for patients.”

Source: PRNewswire

The post Octagos Launches Ask Atlas™, the First AI Tool Built for Device Clinics to Ask Questions of Their Own Data appeared first on ITDigest.

According to the company’s announcement, all the above-mentioned updates are going to allow healthcare companies to get access to intelligence more easily and incorporate it into sales, marketing, product development, and strategy creation processes. Through integration of healthcare intelligence into common business processes, companies will be able to spot different market opportunities and engage with the healthcare landscape better.

One of the most important improvements introduced by Definitive Healthcare includes expanding the Atlas All-Payor Claims dataset. Now the database will contain more details about various types of healthcare activities, diagnoses, and payor information. Combined with the company’s provider affiliation and reference data, the claims intelligence offers a more complete view of healthcare networks, referral relationships, and provider activity.

Also Read: Speech Processing Solutions Unveils Philips SpeechLive Health for Real-Time Clinical Documentation

The company also announced a new integration with HubSpot, allowing users to access healthcare reference, financial, clinical, and affiliation data directly within the CRM platform. The integration is designed to help sales and marketing teams improve prospecting and targeting efficiency.

“Working directly with Definitive Healthcare to integrate their data into our HubSpot environment not only saved time and money we had been spending on a third-party integrations partner, but also helped us to add new fields, enabling insights into organizational affiliations, new markets, and prospective pricing models,” said Andrea Weiss, vice president of marketing at Medisolv. “The DH team was great to work with and made the integration easy to set up.”

Additionally, Salesforce users, including organizations leveraging Agentforce Health and Agentforce Life Sciences, can now access affiliated healthcare professional data directly inside Salesforce through Definitive Connect. The enhancement enables teams to identify and engage physicians and healthcare professionals more effectively using specialty, location, and affiliation data.

Definitive Healthcare also unveiled new AI-powered search capabilities that allow users to interact with healthcare datasets using conversational queries. The company said these features will reduce manual research efforts while helping teams quickly uncover relevant organizations, experts, and healthcare professionals across the industry.

The post Definitive Healthcare Expands Platform With New AI, CRM, and Claims Data Capabilities appeared first on ITDigest.

Building custom EMR workflows is notoriously labor-intensive, given the rigidity of existing systems and the complexity of healthcare data architecture and integration frameworks. Canvas solves this with its SDK and Deep Unified Data Architecture, dramatically lowering the cost for healthcare organizations to build their own custom EMR on the Canvas platform. With Studio, the final barrier is removed: any end user can extend and customize the EMR without software engineering skills. What once required a multi-year project involving engineers, product managers and designers can now be completed by clinicians and staff in a few hours.

A primary care practice, for example, can use Studio to align the requirements of value-based care programs they participate in with coding automation in their visit notes. A psychiatry practice could build custom visualizations of PHQ-9 or GAD-7 survey results, and automate tasks for patient follow-up based on specified quantitative thresholds of results. A weight-loss practice could create context-aware automation of GLP-1 treatment plans, enabling standing orders for common treatment programs. These reduce costly back and forth within the practice and reduce cognitive burden on clinicians, allowing the care team to operate at the top of their license while removing administrative costs.

Also Read: Basata Raises $21M Series A to Rebuild the $1T Operational Layer of American Healthcare

“Unlocking the benefits of healthcare AI in traditional medical groups and specialty practices requires the right tools and context to be available to agents,” said Adam Farren, CEO of Canvas Medical. “We’ve built the Canvas SDK to provide that, and Studio unlocks this value for end users. Clinicians and staff can apply their domain expertise to create more personalized and adaptable EMR workflows. In the immediate term, we expect a lot more EMR customization to happen a lot faster, and beyond that, we expect our customers to begin using their specific clinical and operational knowledge to start building their own custom agents.”

Key capabilities of Studio include:

• Deep access to context: Built on the Canvas platform, Studio gives access to the structured patient data, clinical workflows and controls that make up a patient’s medical record.
• Best-in-class AI-assisted coding tools: Studio is built with Anthropic’s tools and models, and will continue to improve as the quality and efficiency of models for AI-assisted coding get better.
• Natural language interface: Users describe what they want to build in words, and Studio generates code, deploys to a sandbox instance and enables rapid iteration without command-line tools or developer environment setup.
• Agentic workflow automation: Plugins built in Studio can integrate directly with large language models and third-party AI services to automate clinical, operational and financial workflows.
• Open source reference plugins: Canvas has published a library of prebuilt, open source reference plugins that serve as a jumping-off point for users of Studio to build their own tailored versions, quickly and effectively.

Source: PRNewswire

The post Canvas Medical Launches Studio to Enable Clinicians and Operators to Customize and Extend EMR Workflows in Canvas appeared first on ITDigest.

Also Read: Clinical AI Launches MAIA Prescreening on Google Cloud Marketplace to Accelerate Clinical Trials 

“We are pleased to see the FDA validate the advantages that have been clear to us from our first engagements with NanoMosaic,” said Gaurav Venkataraman, Trisk Bio CEO. “Trisk is oriented around helping our clients become successful by providing high-quality material and de-risking manufacturing from the start. Legacy AAV analytics can misread critical quality attributes by orders of magnitude. It’s critical that our clients’ programmes rest on technology yielding the most accurate possible measurements.”

Read More: Trisk Bio and NanoMosaic Announce Partnership for Advanced AAV Analytics

The post Trisk Bio and NanoMosaic Partner to Strengthen AAV Analytics for Gene Therapy Manufacturing appeared first on ITDigest.

Basata’s AI agents handle the administrative work still running on fax machines and phone calls, like referrals, intake, patient scheduling, and follow-up end to end. A referral arrives by fax, Basata extracts the patient details and creates a chart in the EHR, an AI voice agent calls the patient, and the appointment is booked in minutes instead of weeks. The company has served more than 500,000 patients to date, including 100,000 in the past month, and works with providers some of the largest specialty groups in the country across cardiology, urology, gastroenterology, ophthalmology, and growing.

Practices using Basata process 100% of incoming referrals the same day, unlock 50% more administrative labor capacity, and reduce time-to-first-patient-contact from weeks to minutes. Roughly 70% of new sales come from customer referrals.

“Healthcare administration is one of the most consequential and least supported workforces in America,” said Kaled Alhanafi, co-founder and CEO of Basata. “We didn’t build Basata to replace administrators. We built it for them. ‘Basata’ is Arabic for simplicity, and that is what these teams deserve.”

Also Read: Ibex Medical Analytics Establishes Biopharma Advisory Board to Advance AI-Powered Precision Diagnostics

Basata’s founding team came together around a shared conviction that healthcare’s biggest failures aren’t clinical, they’re operational. The country’s clinicians and administrators are world-class; the tools they have been handed are not. CEO Kaled Alhanafi lost his mother as a young adult to a healthcare administrative error. Co-founder Chetan, a former principal engineer at Medtronic, watched his wife wait months to see a cardiologist. Co-founder Vivin, a Computer Science PhD, saw his wife endure the same broken referral process.

That conviction shapes how the company builds. “Our Forward-Deployed Engineer returned from two weeks onsite at a customer site, eyes bloodshot, after manually processing referrals and faxes all day,” said Chetan Patel, co-founder and president of Basata. “It proved that if you aren’t in the trenches, you’ll never grasp how intense this workload is. Building in a bubble fails. We design tech that works because we are on the ground with our customers. This is why so many practices are trusting us with their workflows.”

Customers feel the difference. “Before Basata, we regularly had a backlog of 500+ unprocessed referrals, some waiting for months,” said Rich Bondi, CEO of Southwest Cardiovascular Associates. “Once Basata came in, the backlog went to zero. We’ve seen an 18% boost in new patient conversions because patients are contacted right away. Basata truly transformed our patient care.”

The new funding will enable Basata to scale what’s already working in tackling the $1 trillion operational layer of US healthcare end to end, replacing the patchwork of point solutions practices have stitched together with a single system built alongside the administrators who use it every day.

“It’s 2026, self-driving cars can navigate my city, but patients still have to fight through hold music and fax machines to get care,” said Alhanafi. “That’s the disconnect we’re fixing. In the next decade, healthcare operations will become fully autonomous. Intake, scheduling, coordination, and billing will just happen in the background, and patients will finally experience what exceptional healthcare actually feels like.”

Source: PRNewswire

The post Basata Raises $21M Series A to Rebuild the $1T Operational Layer of American Healthcare appeared first on ITDigest.

The formation of the Advisory Board reflects Ibex’s strategic expansion into biopharma and its commitment to partnering with industry leaders to advance AI-driven biomarker development and precision diagnostics. As oncology rapidly evolves toward antibody-drug conjugates (ADCs) and other targeted therapies, the need for precise, reproducible biomarker quantification and scoring has become increasingly critical. The Board will provide strategic and scientific guidance as the company expands its Biopharma Services offering to support partners across the full lifecycle, from early biomarker and AI-powered companion diagnostics (CDx) development through clinical validation and global deployment via Ibex’s established clinical market.

“The complexity of cancer biology today requires more than just research prototypes; it demands practical, rigorous tools that can transition seamlessly from the lab to the clinic,” said Joseph Mossel, Co-Founder and President of Ibex Medical Analytics. “We are grateful to have Dr. Tarantino and Dr. March join us. Their deep expertise ensures Ibex remains grounded in the practical needs of pharmaceutical development. By leveraging our established clinical network, we are able to reduce risk in clinical development and expand market reach for our partners, moving beyond early-stage AI concepts toward reliable, clinical-grade deployment.”

Also Read: IonQ Launches Commercial InSAR Capability, Enabling Automated, Millimeter-Scale Earth Monitoring

Ruth March, PhD, OBE, FMedSci, FRSB, joins the board following a transformative tenure as Senior Vice President of Precision Medicine and Biosamples at AstraZeneca. Dr. March is a pioneer in the field, having led the approval of more than 70 companion diagnostics for six launched drugs across major global markets. Her career is marked by industry firsts, including the world’s first approval of circulating tumor DNA (ctDNA) to guide therapy and the development of digital pathology biomarkers as companion diagnostics. An expert in population genomics, she also initiated AstraZeneca’s genomics initiatives, utilizing machine learning to analyze millions of genomes. Her contributions to the life sciences were recognized with an OBE for her leadership during the COVID-19 pandemic.

“In my role at AstraZeneca, I saw firsthand the transformative potential of AI to accelerate diagnostics and advance precision medicine,” said Dr. March. “I worked with Ibex for many years and now feel privileged to continue to support them in an advisory role. Their technology has the potential to deliver precise, reproducible biomarker quantification and scoring, combined with a proven global clinical footprint that enables rapid translation from development to real-world use.”

Paolo Tarantino, MD, PhD, is a distinguished breast medical oncologist and clinical researcher. He currently serves as a Research and Clinical Fellow at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Tarantino’s work is at the forefront of the ADC revolution, specifically focusing on mechanisms of action and the development of novel predictive biomarkers to increase treatment precision. A prolific academic, he has published over 100 scientific articles and is a key contributor to numerous clinical trials and preclinical investigations aimed at optimizing outcomes for breast cancer patients.

Ibex’s expanded Biopharma Services offering builds on a proven pharma partnership model, exemplified by the development of Ibex Breast HER2, which progressed from algorithm development through clinical validation, regulatory certification, and real-world deployment using Ibex’s end-to-end capabilities. By combining robust quantification and customizable scoring approaches with a regulatory-grade platform and global clinical deployment footprint, Ibex enables pharmaceutical partners to develop, validate, and scale AI-driven diagnostics with confidence, from early development through commercialization.

SOURCE: Businesswire

The post Ibex Medical Analytics Establishes Biopharma Advisory Board to Advance AI-Powered Precision Diagnostics appeared first on ITDigest.

By leveraging Definitive Healthcare data and insights, Emporia has significantly expanded its ability to recruit healthcare executives, administrators, and technical decision makers with greater precision alongside NPI-verified physicians and clinical staff.

“Healthcare decision making is spread across C-suite executives, IT directors, procurement teams and clinical leaders,” said Christopher Hughes, Founding Product Manager at Emporia Research. “Working with Definitive Healthcare gives us the ability to target these audiences with a level of specificity that hasn’t existed in research recruitment before.”

Precision Targeting for Healthcare Decision Makers

By leveraging data from Definitive Healthcare, Emporia’s targeting capabilities now include:

• Institutional role and title — hospital executives, administrators, department heads and IT decision makers
• Organizational affiliations — health systems, hospitals, ambulatory surgery centers and group practices
• Prescribing behavior and procedure volume
• Clinical trial participation and research activity
• Financial relationships with manufacturers and device companies
• Credentialing, board certifications, and license verification

Also Read: OpenEvidence Introduces Dotflows: AI-Native Customization For Every Clinician

This allows research teams to move beyond broad specialty targeting to reach the specific individuals who influence purchasing, adoption and policy within healthcare organizations.

Built on Verified Identity

Emporia’s healthcare recruitment builds on the company’s proven data quality infrastructure — including LinkedIn verification, proprietary fraud detection and NPI registry validation — ensuring every participant has the professional credibility to back up who they claim to be.

“Definitive delivers highly trusted data across the healthcare industry,” said Jake Roeland, Co-Founder and CTO of Emporia Research. “Combined with our verification stack, we’re giving clients confidence that they’re hearing from the executives and decision makers who actually shape healthcare outcomes.”

Source: PRNewswire

The post Emporia Research Enhances Healthcare Targeting Capabilities, Leveraging Definitive Healthcare Data and Insights appeared first on ITDigest.

Evidence-based medicine is universal—but its application is not. Clinical practice is shaped by differences in specialty, care setting, patient population, and individual preference, and supporting high-quality care means embracing this diversity. In traditional EHRs, dot phrases begin to address this need by allowing clinicians to define and share simple copy/paste text and templates. Dot phrases have become a valuable part of many clinicians’ practice, supporting personalized workflows that match the way each provider practices.

Dotflows represent the extension of dot phrases for full natural language customization in the AI-native era. Dotflows are reusable natural language prompts that customize how OpenEvidence responds. This simple concept enables a wide range of customization and personalization capabilities, expanding to the limits of clinician creativity. Some example uses include personalizing the response style, pre-defining recurring clinical context, and running structured workflows. Clinicians can create their own Dotflows or browse Dotflows shared and used by other clinicians in the community.

Also Read: HMA Acquires HealthTech Solutions, Expanding Technology Capabilities and Medicaid Expertise

“The value of any clinical tool depends on how well it fits into the way a clinician actually practices,” said Dr. Mondira Ray, SVP of Clinical Informatics at OpenEvidence. “Dotflows let users define that fit, encoding their personal styles and mental models into the platform itself.”

Clinicians invoke Dotflows by typing “.” in the search bar, or by setting them as defaults for all queries. Over time, these reusable commands enable OpenEvidence to become increasingly aligned with each clinician’s preferences and practice patterns.

The release also establishes a living library of community-created Dotflows. Clinicians can browse the library, clone Dotflows from the library, and share their own Dotflows with the broader community.

Source: BusinessWire

The post OpenEvidence Introduces Dotflows: AI-Native Customization For Every Clinician appeared first on ITDigest.

Also Read: WellStack and Healthcare Systems of America Partner to Build Unified Data Foundation for AI-Driven Healthcare Analytics

In one oncology case, enrollment rose by 80%. This boost led to more revenue from improved screening capabilities. “Bringing Clinical AI to Google Cloud Marketplace will help customers quickly deploy, manage, and grow the company’s MAIA Prescreening solution on Google Cloud’s trusted, global infrastructure,” said Dai Vu, Managing Director, Marketplace & ISV GTM Programs at Google Cloud. The solution also supports broader workflows such as trial simulations, document processing, and multilingual capabilities, further enhancing clinical operations.

Read More: Clinical AI Announces the Launch of MAIA Prescreening on Google Cloud Marketplace

The post Clinical AI Launches MAIA™ Prescreening on Google Cloud Marketplace to Accelerate Clinical Trials appeared first on ITDigest.

Also Read: Databricks and Fivetran Bring Agentic AI to Streamline Healthcare Referral Management

By standardizing data across systems, HSA aims to strengthen operational visibility, financial outcomes, and scalability of analytics capabilities. “As healthcare systems continue to evolve, the ability to unify and activate data across the enterprise becomes a strategic priority. By partnering with WellStack to establish a modern data foundation, we are creating the infrastructure needed to improve operational transparency, strengthen financial performance, and support the next generation of analytics and AI-enabled insights,” said David Colarusso, CIO, Healthcare Systems of America.

Read More: WellStack Partners with Healthcare Systems of America to Establish a Unified Data Foundation and Enable Enterprise Analytics

The post WellStack and Healthcare Systems of America Partner to Build Unified Data Foundation for AI-Driven Healthcare Analytics appeared first on ITDigest.